JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266843

Human RAB13 knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

RAB13 KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 7 bp deletion in exon 1. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.

View Alternative Names

Cell growth-inhibiting gene 4 protein, GIG4, Growth inhibiting gene 4 protein, RAB13 member RAS oncogene family, RAB13_HUMAN, RAS associated protein RAB13, Ras-related protein Rab-13

3 Images
Western blot - Human RAB13 knockout HEK-293T cell line (AB266843)
  • WB

Lab

Western blot - Human RAB13 knockout HEK-293T cell line (AB266843)

Lanes 1-4 : Merged signal (red and green). Green - ab205528 observed at 24 kDa. Red - loading control ab8245 observed at 36 kDa.

ab205528 Anti-Rab13 antibody [EPR14110(2)] was shown to specifically react with Rab13 in wild-type HEK-293T cells. Loss of signal was observed when knockout cell line ab266843 (knockout cell lysate ab258159) was used. Wild-type and Rab13 knockout samples were subjected to SDS-PAGE. ab205528 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated overnight at 4° at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-RAB13 antibody [EPR14110(2)] (<a href='/en-us/products/primary-antibodies/rab13-antibody-epr141102-ab205528'>ab205528</a>) at 1/1000 dilution

Lane 1:

Wild-type HEK-293T (Human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate at 20 µg

Lane 2:

RAB13 knockout HEK-293T (Human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell lysate at 20 µg

Lane 2:

Western blot - Human RAB13 knockout HEK-293T cell line (ab266843)

Lane 3:

HAP1 whole cell lyate at 20 µg

Lane 4:

HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-800cw-preadsorbed-ab216773'>ab216773</a>) at 1/10000 dilution

Predicted band size: 23 kDa

Observed band size: 24 kDa

false

Cell Culture - Human RAB13 knockout HEK-293T cell line (AB266843)
  • Cell Culture

Lab

Cell Culture - Human RAB13 knockout HEK-293T cell line (AB266843)

Representative images RAB13 knockout HEK293T cells, low and high confluency examples (top left and right respectively) and wild-type HEK293T cells, low and high confluency (bottom left and right respectively) showing typical adherent, epithelial-like morphology. Images were captured at 10X magnification using a EVOS M5000 microscope.

Sanger Sequencing - Human RAB13 knockout HEK-293T cell line (AB266843)
  • Sanger seq

Unknown

Sanger Sequencing - Human RAB13 knockout HEK-293T cell line (AB266843)

Homozygous : 7 bp deletion in exon1

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 7 bp deletion in exon 1

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266843-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266843-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab266843 Human RAB13 knockout HEK-293T cell line", "number":"AB266843-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab266843-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266843 Human RAB13 knockout HEK-293T cell line", "number":"AB266843-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255449 Human wild-type HEK-293T cell line", "number":"AB266843-CMP02" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266843-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266843 Human RAB13 knockout HEK-293T cell line", "number":"AB266843-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266843-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266843 Human RAB13 knockout HEK-293T cell line", "number":"AB266843-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
RAB13
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

RAB13 also known by the names YPT13 and RAB11FIP5 is a small GTPase from the RAB family with a molecular mass of approximately 23 kDa. It localizes to both the cytosol and various membrane compartments. Expressed broadly in different tissues including epithelial tissues and fibroblasts RAB13 plays an active role in vesicle trafficking processes. It primarily modulates the dynamics of vesicle formation transportation and fusion making it critical for maintaining cellular membrane identity and homeostasis.
Biological function summary

RAB13 influences cell surface dynamics by controlling the trafficking of proteins to the plasma membrane. It participates in forming complexes with other RAB proteins ensuring precise membrane delivery and recycling. As a result RAB13 assists in cell junction maintenance and tight junction stability enabling proper cell polarization and epithelial barrier function. This function is essential for processes like cell migration and tissue integrity.

Pathways

The role of RAB13 in intracellular trafficking links it to essential biological pathways such as the actin cytoskeleton regulation and the signaling of the epithelial-to-mesenchymal transition (EMT). In the actin regulation pathway RAB13 closely interacts with proteins like RHOA and CDC42 which assist in reorganizing the cytoskeleton essential for cell movement. For the EMT process RAB13 plays a part in modulating the cellular adherence and motility pathways which are critical during development and repair mechanisms.

The dysregulation of RAB13 expressions has connections to cancer progression and neurological disorders. Studies show that altered RAB13 activity can contribute to invasive cancer phenotypes such as in breast cancer by facilitating abnormal epithelial cell movement. Additionally improper RAB13 function links to neurological conditions where axonal transport is disrupted highlighting a connection with proteins like TAU which similarly plays a role in the maintenance of the neuronal cytoskeleton.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com